Modern drug development approaches that integrate functional plans with larger business goals are needed for success in early ...

Vivani Medical is developing GLP-1 subdermal implants that aim to provide a consistent therapeutic dose for six months, and ...

Adapting to uncertainty over product review timelines at FDA could complicate M&A for pharma buyers and sellers, especially ...

Social proof, the behavioral science concept where people look to others for guidance in uncertain situations, plays a critical role in how patients decide whether to join a study. When patients hear ...

It was the summer of 2007 when Chris Anzalone, Ph.D., got a call from Arrowhead Research Company. At the time, Anzalone was working as CEO of the Bennet Group, a private equity firm in Washington, D.C ...

Mike Fuller & Kim Kennedy Biotechnology companies are in an exceptionally competitive field, with multiple companies competing against each other for a chance to market similar innovative therapeutics ...

In the dynamic pharmaceutical industry, successful product launches are critical to business success. For small and midsized biotech firms, where the reliance on a few key assets is high, the stakes ...

For people living with schizophrenia, the current drug treatment landscape is filled with cracks, crevices, and canyons that prevent a majority of patients from reaching anything close to a normal ...

With six consecutive years of profitability (ahem, soon to be seven) and a market cap of nearly $13 billion, Genmab A/S represents one of Europe’s brightest biotech triumphs. But such wasn’t always ...

The number of psychedelic drug developers reaching Phase 2 and Phase 3 clinical trials is growing, in recognition of the level of unmet need in many mental health disorders and other conditions. Those ...